Browsing by Author "Mohamed, Amal Ahmed"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial
    (Frontiers Media S.A., 2023-03) Mohamed, Amal Ahmed; Abdel Halim, Ahmed; Mohamed, Sahar; Mahmoud, Seham Mohamed; Eldemiry, Eman Mohamed Bahgat; Mohamed, Rasha Sobh; Shaheen, Mahmoud Maamoun; Naguib, Gina G; Muharram, Nashwa M; Khalil, Mona G; Saed, Salma; Ibrahim, Randa; Seif, Ahmed Salah; Kamal, Noha; Nasraldin, Karima; Abdelrahman, Ali Elsaid; El Borolossy, Radwa
    Background and Aim: Non-alcoholic fatty liver (NAFLD) is one of the most common progressive metabolic disorders worldwide. There are increasing scientific interests nowadays for the association between vitamin D status and Non-alcoholic fatty liver. Earlier studies have revealed that vitamin D deficiency is highly prevalent in Non-alcoholic fatty liver patients that contributes to poor outcomes. Hence, the present study aimed to assess the efficacy and safety of oral cholecalciferol on Non-alcoholic fatty liver patients. Subjects and Methods: This study was conducted on 140 patients that were randomized either to group 1 that received the standard conventional therapy in addition to placebo or group 2 that received the standard conventional therapy in addition to cholecalciferol during the 4 months study period. Results: At the end of the study group 2 revealed significant decrease (p < 0.05) in the mean serum level of TG, LDL-C, TC, hsCRP as compared to their baseline results and group 1 results. Additionally, a significant improvement in the serum levels of ALT (p = 0.001) was seen in group 2 at the end of the study when compared to group 1. Whereas group 1 did not show any change in these parameters when compared to group 2 and their baseline results.Conclusion: Cholecalciferol was shown to have beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients. Clinical Trial Registration: https://prsinfo.clinicaltrials.gov/prs-users-guide.html, identifier NCT05613192
  • Thumbnail Image
    Item
    Evaluation of Expressed MicroRNAs as Prospective Biomarkers for Detection of Breast Cancer
    (MDPI, 23/03/2022) Mohamed, Amal Ahmed; Allam, Ahmed E; Aref, Ahmed M; Mahmoud, Maha Osama; Eldesoky, Noha A; Fawazy, Naglaa; Sakr, Yasser; Sobeih, Mohamed Emam; Albogami, Sarah; Fayad, Eman; Althobaiti, Fayez; Jafri, Ibrahim; Alsharif, Ghadi; El-Sayed, Marwa; Abdelgeliel, Asmaa Sayed; Abdel Aziz, Rania S
    Background: Early detection and screening of breast cancer (BC) might help improve the prognosis of BC patients. This study evaluated the use of serum microRNAs (miRs) as non- invasive biomarkers in BC patients. Methods: Using quantitative real-time polymerase chain reaction, we evaluated the serum expression of four candidate miRs (miR-155, miR-373, miR-10b, and miR- 34a) in 99 Egyptian BC patients and 40 healthy subjects (as a control). The miRs expression was correlated with clinicopathological data. In addition, the sensitivity and specificity of the miRs were determined using receiver operating characteristic (ROC) curve analysis. Results: Serum miR-155, miR-373, and miR-10b expression were significantly upregulated (p < 0.001), while serum miR-34a was downregulated (p < 0.00) in nonmetastatic (M0) BC patients compared to the control group. In addition, serum miR-155 and miR-10b were upregulated in BC patients with large tumor sizes and extensive nodal involvement (p < 0.001). ROC curve analysis showed high diagnostic accuracy (area under the curve = 1.0) when the four miRs were combined. Serum miR-373 was significantly upregulated in the human epidermal growth factor 2–negative (p < 0.001), estrogen receptor–positive (p < 0.005), and progesterone receptor (PR)-positive (p < 0.024) in BC patients, and serum miR-155 was significantly upregulated in PR-negative (p < 0.001) BC patients while both serum miR-155 and miR-373 were positively correlated with the tumor grade. Conclusions: Circulating serum miR-155, miR-373, miR-10b, and miR-34a are potential biomarkers for early BC detection in Egyptian patients and their combination shows high sensitivity and specificity.